Target Name: USP17L2
NCBI ID: G377630
Other Name(s): USP17 | Dub3 | ubiquitin carboxyl-terminal hydrolase 17-like protein 2 | Deubiquitinating enzyme 17-like protein 2 | ubiquitin specific peptidase 17-like 2 | Ubiquitin specific peptidase 17 like family member 2 | ubiquitin thiolesterase 17-like protein 2 | ubiquitin thioesterase 17-like protein 2 | Ubiquitin carboxyl-terminal hydrolase 17 | Ubiquitin-specific-processing protease 17-like protein 2 | ubiquitin-specific-processing protease 17-like protein 2 | Deubiquitinating protein 3 | U17L2_HUMAN | deubiquitinating enzyme 3 | deubiquitinating protein 3 | DUB-3 | ubiquitin specific peptidase 17 like family member 2 | DUB3 | Ubiquitin thioesterase 17-like protein 2 | deubiquitinating enzyme 17-like protein 2

USP17L2: A Potential Drug Target and Biomarker

USP17L2 (Uncarcinoinearinib) is a non-steroidal anti-inflammatory drug (NSAID) that is currently being investigated as a potential drug target and biomarker for various diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and chronic pain. In this article, we will discuss the potential mechanisms of action of USP17L2, its potential as a drug target, and its potential as a biomarker for these diseases.

Mechanisms of Action

USP17L2 is a small molecule that is derived from the uterine lining. It has been shown to have anti-inflammatory and pain-relieving effects in animal models of RA, IBD, and chronic pain. USP17L2 works by blocking the production of prostaglandins, which are hormone-like substances that contribute to inflammation and pain.

One of the mechanisms by which USP17L2 works is by inhibiting the production of prostaglandin E2 (PGE2). PGE2 is a pro-inflammatory mediator that is produced by the body's immune system in response to injury or inflammation. It is involved in the recruitment of immune cells to the site of inflammation and is a key factor in the development of pain and inflammation.

In addition to inhibiting PGE2 production, USP17L2 has been shown to block the activity of COX, a enzyme that is involved in the production of prostaglandins. COX enzymes are involved in the regulation of pain and inflammation and are found in all tissues throughout the body. By inhibiting the activity of COX, USP17L2 has been shown to reduce inflammation and pain.

Potential Drug Target

The potential drug target for USP17L2 is the production of prostaglandins. Prostaglandins are involved in the regulation of many physiological processes in the body, including inflammation and pain. They are produced by the body's immune system in response to injury or inflammation and play a key role in the development of pain and inflammation.

By inhibiting the production of prostaglandins, USP17L2 has been shown to have anti-inflammatory and pain-relieving effects. This suggests that USP17L2 could be an effective drug against inflammatory and painful conditions.

Potential Biomarker

One of the challenges in the development of new drugs is the lack of specific and reliable biomarkers that can be used to monitor the effectiveness of these drugs. USP17L2 is an ideal candidate for use as a biomarker because it is produced by the body and can be easily measured in the body.

In addition, USP17L2 has been shown to have a wide range of potential biomarkers. For example, studies have shown that USP17L2 can be used as a biomarker for RA, IBD, and chronic pain. The levels of USP17L2 in these conditions are often elevated and can be used as a marker for the severity of these conditions.

Conclusion

In conclusion, USP17L2 is a small molecule that has been shown to have anti-inflammatory and pain-relieving effects in animal models of RA, IBD, and chronic pain. Its potential as a drug target and biomarker makes it an attractive candidate for further study. Further research is needed to determine the exact mechanisms of action of USP17L2 and its potential as a drug and biomarker.

Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 2

Functions: Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes. Regulates cell proliferation by deubiquitinating and inhibiting RCE1 thereby controlling the small GTPases NRAS and HRAS localization and activation. In parallel, mediates deubiquitination of CDC25A, preventing CDC25A degradation by the proteasome during the G1/S and G2/M phases promoting cell-cycle progression. Also regulates cell proliferation and apoptosis through deubiquitination of SUDS3 a regulator of histone deacetylation. Through activation of the Rho family GTPases RAC1A, CDC42 and RHOA, regulates cell migration. Through the cleavage of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains of the cytoplasmic innate immune receptors RIGI and IFIH1 stimulates the cellular response to viral infection

More Common Targets

USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7